

1FW

Attorney's Docket No. 007157/276516

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Lollar
Appl. No.: 10/813,507
Filed: 3/30/04
For: NUCLEIC ACID AND AMINO ACID SEQUENCES ENCODING HIGH-LEVEL EXPRESSOR FACTOR VIII POLYPEPTIDES AND METHODS OF USE

Confirmation No.: 5299
Art Unit: 1645
Examiner: To Be Assigned



Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
CITATION UNDER 37 C.F.R. § 1.97

Sir:


Attached is a list of documents on form PTO-1449. In accordance with the Office waiver published July 11, 2003, copies of the cited U.S. patents and patent application publications are not enclosed. Applicant does enclose copies of any cited foreign patent documents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

Respectfully submitted,


Kelly J. Williamson
Patent Agent
Registration No. 47,179

<p>CUSTOMER NO. 00826 ALSTON & BIRD LLP Bank of America Plaza 101 South Tryon Street, Suite 4000 Charlotte, NC 28280-4000 Tel Raleigh Office (919) 862-2200 Fax Raleigh Office (919) 862-2260</p>	<p>CERTIFICATE OF MAILING</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on July 20, 2004</p> <p>Pamela Lockley</p>
---	---

Substitute for form 1449/PTO (Revised 04/2003)						Complete if Known			
			Application Number		10/813,507		Filing Date		3/30/04
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		First Named Inventor		Lollar		Group Art Unit		1645	
		Examiner Name		To be Assigned		Attorney Docket Number		007157/279516	
Sheet	1	of	2						
U. S. PATENT DOCUMENTS									
Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document			Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear	
	1	US-5,364,771		11-15-1994	Lollar <i>et al.</i>			Whole Document	
	2	US-5,583,209		12-10-1996	Lollar <i>et al.</i>			Whole Document	
	3	US-5,663,060		09-02-1997	Lollar <i>et al.</i>			Whole Document	
	4	US-5,744,446		04-28-1998	Lollar <i>et al.</i>			Whole Document	
	5	US-5,859,204		01-12-1999	Lollar			Whole Document	
	6	US-5,888,974		03-30-974	Lollar <i>et al.</i>			Whole Document	
	7	US-6,180,371		01-30-2001	Lollar			Whole Document	
	8	US-6,376,463		04-23-2002	Lollar			Whole Document	
	9	US-6,458,563		10-1-2002	Lollar			Whole Document	
FOREIGN PATENT DOCUMENTS									
Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document			Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
OTHER DOCUMENTS									
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.							English Language Translation Attached
	10	BARROW, R.T., <i>et al.</i> , "Antigenicity of Putative Phospholipid Membrane-Binding Residues in Factor VIII," <i>Blood</i> , 2001, pp. 169-174, Vol. 97 No. 1.							
	11	BARROW, R.T., <i>et al.</i> , "Reduction of the Antigenicity of Factor VIII Toward Complex Inhibitory Antibody Plasmas Using Multiply-Substituted Hybrid Human/Porcine Factor VIII Molecules," <i>Blood</i> , 2000, pp. 564-568, Vol. 95, No. 2.							
	12	BOWIE, E.J., and C.A. Owen, "The Clinical and Laboratory Diagnosis of Hemorrhagic Disorders," <i>Grune & Stratton, Inc.</i> , Orlando, 1984, pp. 43-72.							
	13	CHANG, J., <i>et al.</i> , "Changing Residue 338 in Human Factor IX from Arginine to Alanine Causes an Increase in Catalytic Activity," <i>The Journal of Biological Chemistry</i> , 1998, pp. 12089-12094, Vol. 273, No. 20, The American Society for Biochemistry and Molecular Biology, Inc., USA.							
Examiner Signature		Date Considered							

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO
(Revised 04/2003)



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/813,507
Filing Date	3/30/04
First Named Inventor	Lollar
Group Art Unit	1645
Examiner Name	To be Assigned
Attorney Docket Number	007157/279516

Sheet	1	of	2
-------	---	----	---

14	DOERING, C.B., <i>et al.</i> , "High Level Expression of Recombinant Porcine Coagulation Factor VIII," <i>The Journal of Biological Chemistry</i> , 2002, pp. 38345-38349, Vol. 277, No. 41, The American Society for Biochemistry and Molecular Biology, Inc., USA.
15	FUNK, W.D., <i>et al.</i> , "Expression of the Amino-Terminal Half-Molecule of Human Serum Transferrin in Cultured Cells and Characterization of Recombinant Protein," <i>Biochemistry</i> , 1990, pp. 1654-1660, Vol. 29, No. 6.
16	HEALEY, J.F., <i>et al.</i> , "Residues Glu2181-Val2243 Contain a Major Determinant of the Inhibitory Epitope in the C2 Domain of Human Factor VIII," <i>Blood</i> , 1998, pp. 3701-3709, Vol. 92, No. 10.
17	HEALEY, J.F., <i>et al.</i> , "Residues 484-508 Contain a Major Determinant of the Inhibitory Epitope in the A2 Domain of Human Factor VIII," <i>The Journal of Biological Chemistry</i> , 1995, pp. 14505-14509, Vol. 270, No. 24.
18	KAUFMAN, R.J., <i>et al.</i> , "Biosynthesis, Assembly and Secretion of Coagulation Factor VIII," <i>Blood Coagulation and Fibrinolysis</i> , 1997, pp. S3-S14, Vol. 8 (Suppl 2), Rapid science Publishers.
19	LIND, P., <i>et al.</i> , "Novel Forms of B-Domain-Deleted Recombinant Factor VIII Molecules Construction and Biochemical Characterization," <i>Eur. J. Biochem.</i> , 1995, pp. 19-27, Vol. 232.
20	LOLLAR, P., "Mapping factor VIII Inhibitor Epitopes Using Hybrid Human/Porcine Factor VIII Molecules," <i>Haematologica</i> , 2000, pp. 26-30, Vol. 85 (Suppl. to n. 10).
21	LUBIN, I.M., <i>et al.</i> , "Elimination of a Major Inhibitor Epitope in Factor VIII," <i>The Journal of Biological Chemistry</i> , 1994, pp. 8639-8641, Vol. 269, No. 12, The American Society for Biochemistry and Molecular Biology, Inc., USA.
22	PRESCOTT, R., <i>et al.</i> , "The Inhibitor Antibody Response is More Complex in Hemophilia A Patients Than in Most Nonhemophiliacs with Factor VIII Autoantibodies," <i>Blood</i> , 1997, pp. 3663-3671, Vol. 89, No. 10.
23	VEHAR, G.A., <i>et al.</i> , "Structure of Human Factor VIII," <i>Nature</i> , 1984, pp. 337-342, Vol. 312.
24	ZHONG, D., <i>et al.</i> , "Some Human Inhibitor Antibodies Interfere with Factor VIII Binding to Factor IX," 1998, pp. 136-142, Vol. 92, No. 1.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.